Chinese Regulators Approve Lynparza for Advanced Ovarian Cancer

China's National Medical Products Administration has approved AstraZeneca and Merck’s Lynparza (olaparib) as a first-line maintenance treatment for newly diagnosed advanced germline or somatic BRCA-mutated epithelial ovarian, fallopian tube or primary peritoneal cancer.

The approval was based on the results of a phase 3 clinical trial in which Lynparza significantly reduced the risk of disease progression or death versus placebo in patients with BRCA-mutated advanced ovarian cancer following platinum-based chemotherapy.

The drug is currently approved in 65 countries, including those in the EU, for the maintenance treatment of platinum-sensitive relapsed ovarian cancer, regardless of BRCA status.